Population pharmacokinetics of intraperitoneal irinotecan and SN ‐38 in patients with peritoneal metastases from colorectal origin
AbstractPeritoneal metastases (PM) are common in patients with colorectal cancer. Patients with PM have a poor prognosis, and for those who are not eligible for cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC), palliative chemotherapy is currently the only option. Recently, we conducted a phase I trial (INTERACT) in which irinotecan was administered intraperitoneally (IP) to 18 patients ineligible for CRS-HIPEC. The primary objective was to evaluate covariates influencing the PK profile of irinotecan and SN-38 after IP administration. Secondly, a population PK model was develope...
Source: CPT: Pharmacometrics and Systems Pharmacology - April 18, 2024 Category: Drugs & Pharmacology Authors: Pascale C. S. Rietveld,
Sebastiaan D. T. Sassen,
Niels A. D. Guchelaar,
Ruben A. G. van Eerden,
Nadine L. de Boer,
Teun B. M. van den Heuvel,
Jacobus W. A. Burger,
Ron H. J. Mathijssen,
Birgit C. P. Koch,
Stijn L. W. Koolen Tags: ARTICLE Source Type: research
Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview
Curr Diabetes Rev. 2024 Apr 16. doi: 10.2174/0115733998294968240405091023. Online ahead of print.ABSTRACTThe discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor. Over the past decade, drugs that impede the functions of vascular endothelial growth factors have established themselves as a standard-of-ca...
Source: Current Diabetes Reviews - April 17, 2024 Category: Endocrinology Authors: Aman Khandelwal K Gowthamarajan Jayabalan Nirmal S Ponnusankar Source Type: research
Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview
Curr Diabetes Rev. 2024 Apr 16. doi: 10.2174/0115733998294968240405091023. Online ahead of print.ABSTRACTThe discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor. Over the past decade, drugs that impede the functions of vascular endothelial growth factors have established themselves as a standard-of-ca...
Source: Current Diabetes Reviews - April 17, 2024 Category: Endocrinology Authors: Aman Khandelwal K Gowthamarajan Jayabalan Nirmal S Ponnusankar Source Type: research
Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview
Curr Diabetes Rev. 2024 Apr 16. doi: 10.2174/0115733998294968240405091023. Online ahead of print.ABSTRACTThe discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor. Over the past decade, drugs that impede the functions of vascular endothelial growth factors have established themselves as a standard-of-ca...
Source: Current Diabetes Reviews - April 17, 2024 Category: Endocrinology Authors: Aman Khandelwal K Gowthamarajan Jayabalan Nirmal S Ponnusankar Source Type: research
Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview
Curr Diabetes Rev. 2024 Apr 16. doi: 10.2174/0115733998294968240405091023. Online ahead of print.ABSTRACTThe discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor. Over the past decade, drugs that impede the functions of vascular endothelial growth factors have established themselves as a standard-of-ca...
Source: Current Diabetes Reviews - April 17, 2024 Category: Endocrinology Authors: Aman Khandelwal K Gowthamarajan Jayabalan Nirmal S Ponnusankar Source Type: research
Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview
Curr Diabetes Rev. 2024 Apr 16. doi: 10.2174/0115733998294968240405091023. Online ahead of print.ABSTRACTThe discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor. Over the past decade, drugs that impede the functions of vascular endothelial growth factors have established themselves as a standard-of-ca...
Source: Current Diabetes Reviews - April 17, 2024 Category: Endocrinology Authors: Aman Khandelwal K Gowthamarajan Jayabalan Nirmal S Ponnusankar Source Type: research
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)
ConclusionIn this trial population of predominantly fit EP, survival was similar to YP despite a proportion receiving less aggressive therapy at diagnosis and recurrence. Advancing age does not appear to be an adverse prognostic factor for glioblastoma when patients are fit for treatment, and a less aggressive approach in selected patients may not compromise outcomes. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - April 17, 2024 Category: Cancer & Oncology Source Type: research
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
CONCLUSION: For patients with advanced non-selective PD-L1 NSCLC, two effective regimens are Pen + CT and Niv + Bev + CT, which rank first in OS and PFS among all patients. Cam + CT and Tor + CT have advantages for OS in patients with SqNSCLC and Non-sqNSCLC, respectively. Niv + Ipi + CT provided the best OS benefit for patients with an ECOG score of 0, while Pem + CT may be the most effective treatment for patients with an ECOG score of 1. Pem + CT has a better effect on female patients and non-smokers. Sin + CT was found to be the most effective treatment for male patients and the smoking subgroup, while Cam + CT was fou...
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yanqing Yang Wei Chen Lixian Dong Lian Duan Pengfei Gao Source Type: research
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
CONCLUSION: For patients with advanced non-selective PD-L1 NSCLC, two effective regimens are Pen + CT and Niv + Bev + CT, which rank first in OS and PFS among all patients. Cam + CT and Tor + CT have advantages for OS in patients with SqNSCLC and Non-sqNSCLC, respectively. Niv + Ipi + CT provided the best OS benefit for patients with an ECOG score of 0, while Pem + CT may be the most effective treatment for patients with an ECOG score of 1. Pem + CT has a better effect on female patients and non-smokers. Sin + CT was found to be the most effective treatment for male patients and the smoking subgroup, while Cam + CT was fou...
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yanqing Yang Wei Chen Lixian Dong Lian Duan Pengfei Gao Source Type: research
Cancers, Vol. 16, Pages 1515: First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)
za Khemissa Akouz
Magali Terme
Côme Lepage
Valérie Boige
Fluropyrimidine monotherapy is an option for some patients with inoperable metastatic colorectal cancer. Unlike bevacizumab, the addition of aflibercept, an antibody acting as an anti-angiogenic agent, has never been evaluated in this context. The aim of the study was to determine whether aflibercept could increase the efficacy of fluoropyrimidine monotherapy without increasing toxicity. This multicenter phase II non-comparative trial evaluated the addition of aflibercept to infusional 5-fluorouracil/folinic acid (LV5FU2 regimen) as first-line treatment ...
Source: Cancers - April 16, 2024 Category: Cancer & Oncology Authors: Jean-Louis Legoux Roger Faroux Nicolas Barri ère Karine Le Malicot David Tougeron V éronique Lorgis V éronique Guerin-Meyer Vincent Bourgeois David Malka Thomas Aparicio Matthieu Baconnier Val érie Lebrun-Ly Jo ëlle Egreteau Fa ïza Khemissa Akouz Ma Tags: Article Source Type: research
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
ConclusionFor patients with advanced non-selective PD-L1 NSCLC, two effective regimens are Pen + CT and Niv + Bev + CT, which rank first in OS and PFS among all patients. Cam + CT and Tor + CT have advantages for OS in patients with SqNSCLC and Non-sqNSCLC, respectively. Niv + Ipi + CT provided the best OS benefit for patients with an ECOG score of 0, while Pem + CT may be the most effective treatment for patients with an ECOG score of 1. Pem + CT has a better effect on female patients and non-smokers. Sin + CT was found to be the most effective treatment for male patients and the ...
Source: Clinical and Translational Oncology - April 16, 2024 Category: Cancer & Oncology Source Type: research
